Glial Fibrillary Acidic Protein and Neurofilament in Children with Cerebral White Matter Abnormalities

Abstract

Glial fibrillary acidic protein (GFAP) is the major structural protein of the intermediate filaments found in glial cells. Increased levels in the cerebrospinal fluid (CSF) have been found to indicate gliosis. Neurofilament (NFL) is a structural element of neurons, mainly found in large myelinated axons. Its presence in the CSF has been suggested to reflect destruction of axons. The aim of this study was to see if GFAP and NFL in the CSF of children with neurological disabilities and an abnormal signal on magnetic resonance imaging (MRI) of the cerebral white matter could be used to clarify the underlying neuropathology. The potential of GFAP and NFL to differentiate a progressive disease from a stationary disorder was investigated, as was the correlation with disability and clinical findings. CSF from 26 children, eleven with progressive and 15 with non-progressive disorders, was analysed. GFAP was increased in all, interpreted to reflect gliosis. NFL was elevated in seven and considered to indicate ongoing neuroaxonal damage as all but one patient were found to have a progressive disease. GFAP did not differentiate between progressive and non-progressive disorders, although low levels were found in stationary and high levels in progressive disorders. The severity of the disability correlated with the NFL levels, but not with the concentration of GFAP.

GFAP · Neurofilament · Children · Leukoencephalopathy · Leukodystrophy

References

• 1 Ahlsen G, Rosengren L, Belfrage M, Palm A, Haglid K, Hamberger A. et al . Glial fibrillary acidic protein in the cerebrospinal fluid of children with autism and other neuropsychiatric disorders.  Biol Psychiatry. 1993;  10 734-743
• 2 Arend A O, Leary P M, Rutherfoord G S. Alexander's disease: A case report with brain biopsy, ultrasound, CT scan and MRI findings.  Clin Neuropathol. 1991;  3 122-126
• 3 Blennow M, Hagberg H, Rosengren L. Glial fibrillary acidic protein in the cerebrospinal fluid: A possible indicator of prognosis in full-term asphyxiated newborn infants?.  Pediatr Res. 1995;  3 260-264
• 4 Duchen L W. General pathology of neurons and neuroglia. Adams JH, Corsellis JAN, Duchen LW Greenfield's Neuropathology. London; Edward Arnold 1984: 1-52
• 5 Ehlers S, Kyllerman M, Rosengren L. Analysis of glial fibrillary acidic protein in the cerebrospinal fluid of children investigated for encephalopathy.  Neuropediatrics. 1994;  3 129-133
• 6 Holmberg B, Rosengren L, Karlsson J E, Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.  Mov Disord. 1998;  1 70-77
• 7 Kristjánsdóttir R, Uvebrant P, Hagberg B, Kyllerman M, Wiklund L M, Blennow G. et al . Disorders of the cerebral white matter in children. The spectrum of lesions.  Neuropediatrics. 1996;  6 295-298
• 8 Kristjánsdóttir R, Uvebrant P, Wiklund L M. Clinical characteristics of children with cerebral white matter abnormalities.  Europ J Paediatr Neurol. 2000;  1 17-26
• 9 Kristjánsdóttir R, Uvebrant P, Lekman A, Månsson J-E. Cerebrospinal fluid markers in children with cerebral white matter abnormalities.  Neuropediatrics. 2001;  32 176-182
• 10 Lycke J N, Karlsson J E, Andersen O, Rosengren L E. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis.  J Neurol Neurosurg Psychiatry. 1998;  3 402-404
• 11 Månsson J-E, Fredman P. White matter neurochemistry: Normal and pathological states. Pantoni L, Inzitari D, Wallin A “The Matter of White Matter”: Clinical and Pathophysiological Aspects of White Matter Disease Related to Cognitive Decline and Vascular Dementia. The Netherlands; Academic Pharmaceutical Production 2000: 275-286
• 12 Rosengren L E, Ahlsen G, Belfrage M, Gillberg C, Haglid K G, Hamberger A. A sensitive ELISA for glial fibrillary acidic protein: Application in CSF of children.  J Neurosci Methods. 1992;  2 - 3 113-119
• 13 Rosengren L E, Karlsson J E, Karlsson J O, Persson L I, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF.  J Neurochem. 1996;  5 2013-2018
• 14 Rosengren L E, Karlsson J E, Sjogren M, Blennow K, Wallin A. Neurofilament protein levels in CSF are increased in dementia.  Neurology. 1999;  5 1090-1093
• 15 Tullberg M, Rosengren L, Blomsterwall E, Karlsson J E, Wikkelso C. CSF neurofilament and glial fibrillary acidic protein in normal pressure hydrocephalus.  Neurology. 1998;  4 1122-1127
• 16 Varho T, Jaaskelainen S, Tolonen U, Sonninen P, Vainionpaa L, Aula P. et al . Central and peripheral nervous system dysfunction in the clinical variation of Salla disease.  Neurology. 2000;  1 99-104